<DOC>
	<DOCNO>NCT00275119</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , oxaliplatin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together oxaliplatin follow radiation therapy , fluorouracil , oxaliplatin work treat patient locally advanced pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine Oxaliplatin Followed By Radiation Therapy , Fluorouracil , Oxaliplatin Treating Patients With Locally Advanced Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient locally advance , nonresectable adenocarcinoma pancreas treat gemcitabine hydrochloride oxaliplatin follow concurrent radiotherapy , fluorouracil , oxaliplatin . Secondary - Determine tolerability regimen , short- long-term , patient . - Determine recurrence-free survival , overall survival , response rate patient treat regimen . - Determine quality life patient treat regimen . - Determine clinical benefit regimen patient . - Determine locoregional metastatic progression-free survival patient treat regimen . OUTLINE : This open-label , multicenter study . - Chemotherapy : Patients receive gemcitabine hydrochloride 100 minute day 1 oxaliplatin IV 2 hour day 2 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Patients restaged day 15-21 fourth course chemotherapy . Patients nonmetastatic disease proceed chemoradiotherapy . - Chemoradiotherapy : Patients undergo radiotherapy 5 day week 5 week . Patients also receive fluorouracil IV continuously week 1-5 oxaliplatin IV 1 hour day 1 , 8 , 15 , 22 , 29 absence disease progression unacceptable toxicity . Quality life assess baseline , restaging , day 28 completion chemoradiotherapy . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 58 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Locally advance , nonresectable disease Residual disease surgical resection ( R1 , R2 ) OR recurrent disease radical surgery No visceral peritoneal metastases No adenocarcinoma bile ducts ampulla Vater PATIENT CHARACTERISTICS : ECOG performance status 02 Stable control pain analgesic Not pregnant nursing Neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time normal OR &lt; 3 mg/dL Creatinine clearance ≥ 40 mL/min Bilirubin ≤ 1.5 time normal Alkaline phosphatase &lt; 5 time normal No medical condition would preclude study treatment No active infection Negative pregnancy test No serious cardiac respiratory disease No uncontrolled persistent hypercalcemia No preexisting neuropathy No biliary gastroduodenal obstruction No malignancy except nonmelanomatous skin cancer , prostate cancer , carcinoma situ cervix bladder No familial , social , geographical , psychological condition would preclude study compliance PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior abdominal radiotherapy ( encompass liver , pancreas , spleen ) At least 2 month since prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>